VCC-001, the most advanced product candidate demonstrated clinical efficacy and a favorable safety profile in several clinical trials. 1, 2, 3, 4 The availability of clinical data that have been obtained in >1000 patients reduces risk of failure of future clinical trials I.
Mechanism of action:
Inducing a specific immune response against the
patientʼs tumour based on the individual antigen profile
to enable the immune system to recognize and attack the tumour.